Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

Nobuki Furubayashi, Takahito Negishi, Akihiro Miura, Nobutaka Nakamura, Motonobu Nakamura Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanCorrespondence: Nobuki Furubayashi Tel +81-92-541-3231Fax +81-92-551-4585Email furubayashi-jua@umin.ac.jpBackground: To...

Full description

Bibliographic Details
Main Authors:	Furubayashi N, Negishi T, Miura A, Nakamura N, Nakamura M
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	Research and Reports in Urology
Subjects:	urothelial carcinoma platinum-based chemotherapy pembrolizumab paclitaxel carboplatin organ-specific therapeutic effect
Online Access:	https://www.dovepress.com/organ-specific-therapeutic-effect-of-paclitaxel-and-carboplatin-chemot-peer-reviewed-article-RRU

Similar Items

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
by: Furubayashi N, et al.
Published: (2021-03-01)

Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)

DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY
by: R. Noviyani, et al.
Published: (2014-01-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
by: Ahmed Gamal Elsayed, et al.
Published: (2017-08-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
by: Hirotoshi Yasui, et al.
Published: (2014-08-01)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
by: R. Kawaguchi, et al.
Published: (2012-04-01)

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients
by: Afandi Charles, et al.
Published: (2016-11-01)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020-11-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-09-01)

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer
by: Blagden Sarah, et al.
Published: (2011-07-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort
by: Rafaela Pirolli, et al.
Published: (2021-05-01)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
by: Primandono Perbowo, et al.
Published: (2019-07-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
by: Mohammad Mobayed, et al.
Published: (2009-11-01)

Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre
by: Sue Cheeseman, et al.
Published: (2020-02-01)

Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combination chemotherapy
by: Tomoyuki Shirase, et al.
Published: (2012-01-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
by: Tomoyuki Araya, et al.
Published: (2020-12-01)

Chemotherapy of ovarian cancer in elderly patients
by: Tiffany A. Troso-Sandoval, et al.
Published: (2015-12-01)

Type of chemotherapy has substantial effects on the immune system in ovarian cancer
by: Ann Vankerckhoven, et al.
Published: (2021-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
by: Laura Williams, et al.
Published: (2009-02-01)

Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
by: Hanan Shawky, et al.
Published: (2014-09-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

Metastatic Intimal Sarcoma of the Pulmonary Artery Sensitive to Carboplatin-Vinorelbine Chemotherapy: Case Report and Literature Review
by: Marie Cantaloube, et al.
Published: (2018-01-01)

Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature
by: Sujen Jayakody, et al.
Published: (2018-08-01)

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy
by: Melek Kandemir, et al.
Published: (2015-12-01)

The Clinical Analysis of First-Line Palitaxel Plus Platinum-Based Chemotherapy to Treat Elderly Non-Small Cell Lung Cancer
by: Tianqing CHU, et al.
Published: (2009-04-01)

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
by: Christian Fuhrmann, et al.
Published: (2020-05-01)

The Clinical Analysis of Paclitaxel at Two Dose Levels plus Carboplatin as the First-line Treatment in Advanced Non-small Cell Lung Cancer
by: Jialin QIAN, et al.
Published: (2011-04-01)

Irreversible laryngeal palsy: An induced complication of carboplatin 450mg/m2 and paclitaxel 250mg/m2 - Case report
by: Rawish Kumar, et al.
Published: (2018-03-01)

Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure
by: Consolación Melguizo, et al.
Published: (2012-12-01)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
by: Toshinobu Hayashi, et al.
Published: (2021-01-01)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
by: Kyotaro Fukuta, et al.
Published: (2021-09-01)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
by: Akiko Ishii, et al.
Published: (2020-06-01)